| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Moxifloxacin-d4 hydrochloride is an analytical standard and has no direct biological target. The unlabeled parent drug, moxifloxacin, targets bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential enzymes for bacterial DNA replication, transcription, and repair. By inhibiting these enzymes, moxifloxacin induces DNA double-strand breaks and bacterial cell death. The deuterium labeling does not alter the biological activity, but the labeled compound is used solely for analytical purposes.
|
|---|---|
| ln Vitro |
Moxifloxacin-d4 hydrochloride is not a drug and has no direct in vitro biological activity. It is used as an internal standard for the quantification of moxifloxacin in biological samples. The unlabeled moxifloxacin is a potent, broad-spectrum fluoroquinolone antibiotic with in vitro activity against Gram-positive and Gram-negative bacteria. MIC values for susceptible strains are typically <1 ug/mL. The deuterated version is not used in bioactivity assays.
|
| ln Vivo |
Not applicable. Moxifloxacin-d4 hydrochloride is not administered in vivo. It is an analytical internal standard used to quantify moxifloxacin in pharmacokinetic and bioequivalence studies. The unlabeled moxifloxacin is an orally active antibiotic used for the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. The deuterated compound is not therapeutic.
|
| Enzyme Assay |
Not applicable. Moxifloxacin-d4 hydrochloride is an analytical standard, not a standard enzyme inhibitor. Its purity (>99%) is assessed by HPLC. The structure is confirmed by ¹H NMR, ¹3C NMR, and mass spectrometry. The deuterium content is determined by mass spectrometry. For analytical method development, a fixed amount of Moxifloxacin-d4 hydrochloride is added to the biological sample as an internal standard before extraction. The peak area ratio of the analyte to the internal standard is used for quantification.
|
| Cell Assay |
Not applicable. Moxifloxacin-d4 hydrochloride is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with the compound (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >500 uM, indicating very low cytotoxicity. The compound is an analytical standard, not a test agent for pharmacological studies.
|
| Animal Protocol |
For pharmacokinetic studies of moxifloxacin, male Sprague-Dawley rats (200-250 g, n=6/group) are administered moxifloxacin hydrochloride orally (20-100 mg/kg) or intravenously (10-20 mg/kg). Blood samples are collected at various time points. Moxifloxacin-d4 hydrochloride is added to the plasma samples as an internal standard before extraction. The concentration of unlabeled moxifloxacin is quantified by LC-MS/MS. PK parameters (Cmax, Tmax, AUC, t½, bioavailability) are calculated.
|
| ADME/Pharmacokinetics |
Moxifloxacin-d4 hydrochloride is an analytical standard, not a drug. The unlabeled moxifloxacin has a molecular weight of 437.89 (free base). Following oral administration, it is well absorbed (bioavailability ~90%), with a half-life of approximately 12 hours in humans. It is distributed into tissues and is eliminated primarily by renal and biliary excretion. For research use, the labeled compound is stored as a powder at -20degC, protected from light.
|
| Toxicity/Toxicokinetics |
For Moxifloxacin-d4 hydrochloride, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at -20degC, sealed, protect from light.
|
| References | |
| Additional Infomation |
Moxifloxacin-d4 hydrochloride (BAY 12-8039-d4; CAS# not assigned; MW ~441) is a research-grade stable isotope-labeled internal standard for the quantification of moxifloxacin. It is not an FDA-approved drug. It is used in LC-MS/MS method development for pharmacokinetic (PK) and bioequivalence (BE) studies. For research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C21H21D4CLFN3O4
|
|---|---|
| Molecular Weight |
441.92
|
| Related CAS # |
Moxifloxacin-d4;2596386-23-9
|
| Appearance |
Solid powder
|
| Synonyms |
BAY 12-8039-d4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2629 mL | 11.3143 mL | 22.6285 mL | |
| 5 mM | 0.4526 mL | 2.2629 mL | 4.5257 mL | |
| 10 mM | 0.2263 mL | 1.1314 mL | 2.2629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
